Clinical Trial Update: Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of ibrutinib, fludarabine, and pembrolizumab in high-risk or relapsed/refractory chronic lymphocytic leukemia/small l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Fludara (fludarabine)
• IMBRUVICA (IBRUTINIB)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: B-Cell Chronic Lymphocytic Leukemia, B-Lymphocytic Leukemia, Chronic | Phase 2 | Status: COMPLETED | Results posted: 2023-04-19